SCHEMBL4775178

SCHEMBL4775178

Cc1ccc(Cl)cc1N1CCN(C(=O)C(N)Cc2cccc(Cl)c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 4/20 0.58
AKT2 P31751 1/20 0.58
AKT3 Q9Y243 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
MC4R P32245 5/20 0.53
MEN1 O00255 2/20 0.53
ALDH1A1 P00352 2/20 0.53
KMT2A Q03164 2/20 0.53
USP2 O75604 3/20 0.53
LMNA P02545 2/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
TSHR P16473 1/20 0.50
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
HSD17B10 Q99714 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4779235 0.94 MAPT (0.52) AKT1AKT2AKT3HDAC8MC4R
SCHEMBL4793769 0.92 MAPT (0.57) AKT1AKT2AKT3MC4RMEN1
SCHEMBL4773546 0.90 MC4R (0.61) AKT1MC4RMEN1ALDH1A1KMT2A
SCHEMBL4770964 0.89 MC4R (0.59) AKT1AKT2AKT3HDAC8MC4R
SCHEMBL4905812 0.87 MEN1 (0.53) MC4RMEN1ALDH1A1KMT2AUSP2
SCHEMBL4793962 0.86 AKT1 (0.59) AKT1AKT2AKT3MC4RMEN1
SCHEMBL4774413 0.86 AKT1 (0.55) AKT1AKT2AKT3HDAC8MC4R
SCHEMBL4778157 0.86 AKT1 (0.56) AKT1HDAC8MC4RMEN1ALDH1A1
SCHEMBL4775603 0.85 MC4R (0.59) AKT1AKT2AKT3HDAC8MC4R
SCHEMBL4776568 0.84 MC4R (0.50) AKT1MC4RMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof HNMT, HDAC5, HDAC4 AKT1 3114/4885AKT2 2960/4885AKT3 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.